SCHEMBL5197994

SCHEMBL5197994

O=C(O)c1ccc2c(C3CCCCC3)c(-c3ccc4cc(-c5ccccc5F)ccc4c3)n(CC(=O)N3CCOCC3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.41
PRKCA P17252 1/20 0.41
MMP12 P39900 1/20 0.41
NR1I2 O75469 1/20 0.40
HRH1 P35367 1/20 0.38
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
SCN9A Q15858 1/20 0.35
CYP2C9 P11712 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HIF1A Q16665 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5197980 0.94 GRIN2B (0.43) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5196861 0.91 GRIN2B (0.39) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5196260 0.91 GRIN2B (0.40) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5223461 0.87 GRIN2B (0.43) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5196039 0.87 GRIN2B (0.43) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5198409 0.86 GRIN2B (0.43) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5439046 0.86 PRKCA (0.44) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5227324 0.86 HRH1 (0.37) GRIN2BPRKCAMMP12NR1I2HRH1
SCHEMBL5227568 0.86 GRIN2B (0.45) GRIN2BPRKCAMMP12NR1I2BRD4
SCHEMBL5934775 0.85 PRKCA (0.39) GRIN2BPRKCAMMP12NR1I2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US claimed
EP-1844042-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2007-10-17 EP disclosed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US disclosed
WO-2006076529-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses HAVCR2, ZC3HAV1, SARS1 GRIN2B 1821/4885PRKCA 4500/4885MMP12 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.